Vertex Pharmaceuticals announced the first accepted medical presentations of the Phase 3 data on the investigational once ...
With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply ...
Biotechnology company Vertex Pharmaceuticals, Inc. (VRTX) announced Thursday that Health Canada has accepted for review its New Drug ...
Vertex Pharmaceuticals’ breakthrough in cystic fibrosis was a medicine that treats just 4% of patients who have the lung disorder. Today, Vertex’s portfolio of blockbuster CF products spans ...
Back in 2019 and early 2020, bluebird bio stock was between $40 and $50 a share, and the latest quote is 48 cents. This ...
Vertex Pharmaceuticals Inc. (VRTX) said that Health Canada has granted Marketing Authorization for CASGEVY (exagamglogene ...
Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...
U.S. News' panel of financial advisors addresses the No. 1 issue on investors' minds in the back half of 2024.
The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback